Physician profile
Peter Van Dyck
NPI 1730275470
$2,746.13
in general payments reported to CMS, 2019-2025
29 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $295 · 2023: $100 · 2024: $539 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859 · Education: $88.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.26 |
| Education | $88.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $402.28 | 2019-2020 | |
| Allergan, INC. | $333.18 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $231.43 | 2019-2024 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $222.47 | 2019-2025 | Rexulti, Abilify Maintena |
| Neos Therapeutics, Lp | $210.99 | 2019-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $151.52 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $143.41 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $126.64 | 2019-2024 | |
| Bausch Health US, LLC | $100.27 | 2019-2024 | Wellbutrin, Aplenzin |
| Neurocrine Biosciences, INC. | $89.57 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.89 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $78.09 | 2024 | Qelbree |
| Lundbeck LLC | $73.00 | 2019-2024 | Rexulti |
| Shire North American Group INC | $72.54 | 2019 | |
| Almatica Pharma LLC | $66.55 | 2024-2025 | Loreev Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $53.17 | 2019-2020 | |
| Abbvie INC. | $43.32 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.18 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $37.01 | 2019-2020 | |
| Alkermes, INC. | $28.58 | 2024 | Aristada, Lybalvi |
| Vertical Pharmaceuticals, LLC | $23.67 | 2019 | |
| Tandem Diabetes Care, INC. | $23.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.55 | 2025 | Austedo Xr |
| Noven Therapeutics, LLC | $18.55 | 2023 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $16.46 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $14.99 | 2024 | Fanapt, Hetlioz |
| Corium, LLC | $14.61 | 2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $12.44 | 2019 | |
| Merck Sharp & Dohme LLC | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Van Dyck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.